PATENT CLAIM ANALYSIS

Application Number: 16133553
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["514", "289000"]

Abstract:
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Claim (Index 1):
A method, comprising treating a human being with dextromethorphan by administering twice daily for at least eight consecutive days a dosage form comprising both dextromethorphan and bupropion to the human being, wherein the human being is an extensive metabolizer of dextromethorphan, wherein after eight consecutive days of administering the dosage form twice daily, the method results in an AUC 0-12  of dextromethorphan that is: 1) at least about 500 ng\u00b7hr/mL and 2) at least 15 times the AUC 0-12  of dextromethorphan that would be achieved by administering the same amount of dextromethorphan twice daily without bupropion for eight consecutive days.

Metadata:
- Claim Count in Document: 68.0
- Percentile: 97.0
- Lexical Diversity: 1.45455
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15688660', '15695995', '15691549', '15645939', '15691532']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8882402062397813
- 35 USC 102 Novelty (BERT): 0.7002387426058718
- Combined Prediction Score: 0.8694400598763904
- Mean Citation Score: 793.7393319999999
- Max Citation Score: 808.8913
- Similarity Product: 725.6144164956212

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test